PTO/SB/08a/b (08-03) Approved for use through 07/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

February 26, 2004.

Complete if Known

10/789,303

Substitute for form 1449A/B/PTO

1

PADEMAR

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Kelly Reed Clark et al. <del>1653</del>- 1633 Art Unit Examiner Name M. Burkhart Attorney Docket Number 28335/40012

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code <sup>2</sup> (#known)	MM-DD-YYYY			
MS		5,622,856	04-22-1997	Natsoulis		
		5,658,776	08-19-1997	Flotte et al.		
		5,658,785	08-19-1997	Johnson		
		5,837,484	11-17-1998	Trempe et al.		
		6,258,595	07-10-2001	Gao et al.		
		6,365,403	04-02-2002	Natsoulis et al.		
	•	6,475,769	11-05-2002	Wilson et al.		
MS		6,541,258	04-01-2003	Allen et al.		

Application Number

First Named Inventor

Filing Date

		FOREI	GN PATENT	DOCUMENTS		
Examiner Cite		Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>6</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	ಗ್
N		WO99/41399	08-19-1999	Wadsworth		
T	•					
			l			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
MS	-	Aitken et al., Hum Gene Therapy, "A Phase I Study of Aerosolized Administration of tgAAVCF to Cystic Fibrosis Subjects with Mild Lung Disease", 12:1907-1916 (2001)	
		Carter et al., AAV Vectors for Gene Therapy, in Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Second Edition (Ed. N. Templeton-Smith), pp. 71-101, Marcel Dekker, New York, 2004	
		Clark et al., Hum Gene Therapy, "Cell Lines for the Production of Recombinant Adeno- Associated Virus", 6:1329-1341 (1995)	
		Clark et al., Gene Therapy, "A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors", 3:1124-1132 (1996)	
		Clark et al., Hum Gene Therapy, "Recombinant Adeno-Associated Viral Vectors Mediate Long-Term Transgene Expression in Muscle", 8(6):659-669 (1997)	
		Clark et al., Hum Gene Therapy, "Highly Purified Recombinant Adeno-Associated Virus Vectors Are Biologically Active and Free of Detectable Helper and Wild-Type Viruses", 10(6):1031-1039 (1999)	
		Fan and Dong, Human Gene Therapy, "Replication of rep-cap Genes Is Essential for the High- Efficiency Production of Recombinant AAV", 8:87-98 (1997)	
		Gao et al., Molecular Therapy, "Rep/Cap Gene Amplification and High-Yield Production of AAV in an A549 Cell Line Expressing Rep/Cap", 5(5):644-649 (2002).	
2		Graham and Prevec. Mol. Biotechnol., "Methods for Construction of Adenovirus Vectors",	

Examiner Signature	mal	8	Date Considered	3-28-06
		<del></del>		

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE spond to a collection of information unless it contains a valid OMB control number.

Sut	ostitute for form 1449A/B/PT	0	· · · · · · · · · · · · · · · · · · ·	Complete if Known		
		_		Application Number	10/789,303	
11	<b>NFORMATION</b>	I DIS	SCLOSURE	Filing Date	February 26, 2004	
S	TATEMENT	3Y <i>A</i>	APPLICANT	First Named Inventor	Kelly Reed Clark et al.	
				Art Unit	1653- 16 33	
l	(Use as many sh	eets as	necessary)	Examiner Name	M. Burkhart	
Sheet	2	of	2	Attorney Docket Number	28335/40012	

	3:207-220 (1995)	
MS	Handbook of Parvoviruses, Vol. I (P. Tjissen, ed.) CRC Press, Boca Raton, pp 255-282 (1989)	
	Leonard and Berns, Virology, "Cloning, Expression, and Partial Purification of Rep78: An	
	Adeno-Associated Virus Replication Protein*, 200:566-573 (1994)	
ļ	Li et al., J. Virol., "Role for Highly Regulated rep Gene Expression in Adeno-Associated Virus	
	Vector Production", 71:5236-5243 (1997)	
	Liu et al., Molecular Therapy, "Selective Rep-Cap Gene Amplification as a Mechanism For High-Titer Recombinant AAV Production From Stable Cell Lines", 2(4):394-403 (2000).	
	Matsushita et al., Gene Therapy, "Adeno-associated virus vectors can be efficiently produced without helper virus", 5:938-945 (1998)	
	Muzyczka, Current Topics in Microbiology and Immunology, "Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells", 158:97-129 (1992)	
	Nony et al., J. Virol., "Novel cis-Acting Replication Element in the Adeno-Associated Virus Type 2 Genome is Involved in Amplification of Integrated rep-cap Sequences", 75(20):9991-9994 (2001).	
	Pereira et al., J. Virol., "The Adeno-Associated Virus (AAV) Rep Protein Acts as Both a Repressor and an Activator to Regulate AAV Transcription during a Productive Infection", 71(2):1079-1088 (1997).	
	Ruffing et al., J. Gen. Virol., "Mutations in the carboxy terminus of adeno-associated virus 2 capsid proteins affect viral infectivity: lack of an RGD integrin-binding motif", 75:3385-3392 (1994)	
	Srivastava et al., J. Virol., "Nucleotide Sequence and Organization of the Adeno-Associated Virus 2 Genome", 45:555-564 (1983)	
MB	Vincent et al., J. Virol., "Analysis of Recombinant Adeno-Associated Virus Packaging and Requirements for rep and cap Gene Products", 71:1897-1905 (1997)	
	Xiao et al., J. Virol. "Production of High-Titer Recombinant Adone Associated Virus Vectors in the Absence of Helper Adenovirus", 72:2224-2232 (1998)	
		_
		_
		-

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner 0 - 1 2-	Date 7.30 A/
Signature CAT CAT	Considered > 20,00

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.